Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease

Journal of Virology

Volumn 86, Issue 18, 2012, Pages 9748-9759

  Remakus, Sanda ^a,b   Rubio, Daniel ^a,c   Ma, Xueying ^a   Sette, Alessandro ^d   Sigal, Luis J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; ISOLEUCYLTHREONYLTYROSYLARGINYLPHENYLALANYLTYROSYLLEUCYLISOLEUCINE; LYSYLSERYLTYROSYLASPARAGINYLTYROSYLMETHIONYLLEUCYLLEUCINE; POLYPEPTIDE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; SERYLISOLEUCYLPHENYLALANYLARGINYLPHENYLALANYLLEUCYLASPARAGINYLISOLEUCINE; SERYLTHREONYLLEUCYLASPARAGINYLPHENYLALANYLASPARAGINYLASPARAGINYLLEUCINE; THREONYLSERYLTYROSYLLYSYLPHENYLALANYLGLUTAMYLSERYLVALINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEASIBILITY STUDY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; MEMORY T LYMPHOCYTE; MOLECULAR DYNAMICS; MOUSE; MOUSEPOX; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS IDENTIFICATION; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; H-2 ANTIGENS; IMMUNIZATION; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; PEPTIDES; VIRAL PROTEINS; VIRAL VACCINES;

ECTROMELIA VIRUS; MUS;

EID: 84866173757     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00981-12     Document Type: Article

References (61)

1. Abbas AK. 1989. Antigen presentation by B lymphocytes: mechanisms and functional significance. Semin. Immunol. 1: 5-12.
2. Amoscato AA, Prenovitz DA, Lotze MT. 1998. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161: 4023-4032.
3. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. 2005. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11: 748-756.
4. Baker DG. 1998. Natural pathogens of laboratory mice, rats, and rabbits and their effects on research. Clin. Microbiol. Rev. 11: 231-266.
5. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. 2007. Apoptosis induced by the lymphocyte effector molecule perforin. Curr. Opin. Immunol. 19: 339-347.
6. Chen W, Drillien R, Spehner D, Buller RM. 1992. Restricted replication of ectromelia virus in cell culture correlates with mutations in virusencoded host range gene. Virology. 187: 433-442.
7. Chowdhury D, Lieberman J. 2008. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu. Rev. Immunol. 26: 389-420.
8. Cole GA, Hogg TL, Coppola MA, Woodland DL. 1997. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection. J. Immunol. 158: 4301-4309.
9. Delano ML, Brownstein DG. 1995. Innate resistance to lethal mousepox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J. Virol. 69: 5875-5877.
10. Fang M, Lanier LL, Sigal LJ. 2008. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog. 4:e30. doi:10.1371/journal.ppat.0040030.
11. Fang M, et al. 2011. CD94 is essential for NK cell-mediated resistance to a lethal viral disease. Immunity. 34: 579-589.
12. Fang M, Sigal L. 2010. Studying NK cell responses to ectromelia virus infections in mice. Methods Mol. Biol. 612: 411-428.
13. Fang M, Sigal LJ. 2005. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J. Immunol. 175: 6829-6836.
14. Fang M, Sigal LJ. 2006. Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host. J. Immunol. 177: 8027-8036.
15. Fenner F. 1949. Mouse-pox: infectious ectromelia of mice. A review. J. Immunol. 63: 341-373.
16. Fenner F, et al. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
17. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. 2009. Principles of virology, 3rd ed. ASM Press, Washington, DC.
18. French AR, Yokoyama WM. 2003. Natural killer cells and viral infections. Curr. Opin. Immunol. 15: 45-51.
19. Fu TM, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. 1997. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71: 2715-2721.
20. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187: 1647-1657.
21. Ge Q, Bai A, Jones B, Eisen HN, Chen J. 2004. Competition for selfpeptide-MHC complexes and cytokines between naive and memory CD8+ T cells expressing the same or different T cell receptors. Proc. Natl. Acad. Sci. U. S. A. 101: 3041-3046.
22. Guidotti LG, Chisari FV. 2001. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19: 65-91.
23. Hamilton SE, Porter BB, Messingham KA, Badovinac VP, Harty JT. 2004. MHC class Ia-restricted memory T cells inhibit expansion of a nonprotective MHC class Ib (H2-M3)-restricted memory response. Nat. Immunol. 5: 159-168.
24. Im EJ, et al. 2011. Protective efficacy of serially up-ranked subdominant CD8 T cell epitopes against virus challenges. PLoS Pathog. 7:e1002041. doi:10.1371/journal.ppat.1002041.
25. Jacoby RO, Bhatt PN, Brownstein DG. 1989. Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus. Arch. Virol. 108: 49-58.
26. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J. 1996. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J. Virol. 70: 8301-8309.
27. Kast WM, et al. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. U. S. A. 88: 2283-2287.
28. Klavinskis LS, Whitton JL, Joly E, Oldstone MB. 1990. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology. 178: 393-400.
29. Klavinskis LS, Whitton JL, Oldstone MB. 1989. Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J. Virol. 63: 4311-4316.
30. Lanier LL. 1998. NK cell receptors. Annu. Rev. Immunol. 16: 359-393.
31. Law M, Putz MM, Smith GL. 2005. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J. Gen. Virol. 86: 991-1000.
32. Lieberman J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3: 361-370.
33. Liu J, et al. 2006. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J. Virol. 80: 11991-11997.
34. Martins LP, Lau LL, Asano MS, Ahmed R. 1995. DNA vaccination against persistent viral infection. J. Virol. 69: 2574-2582.
35. Montasir M, Rabin ER, Phillips CA. 1966. Vaccinia pneumonia in mice. A light and electron microscopic and viral assay study. Am. J. Pathol. 48: 877-895.
36. Moutaftsi M, et al. 2006. A consensus epitope prediction approach identifies the breadth of murine T (CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24: 817-819.
37. Moutaftsi M, et al. 2009. Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur. J. Immunol. 39: 717-722.
38. Murali-Krishna K, et al. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8: 177-187.
39. b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69: 6665-6677.
40. Oldstone MB, Lewicki H, Borrow P, Hudrisier D, Gairin JE. 1995. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J. Virol. 69: 7423-7429.
41. Oldstone MB, et al. 1993. Vaccination to prevent persistent viral infection. J. Virol. 67: 4372-4378.
42. b cells. J. Immunol. 152: 4843-4851.
43. Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM. 2007. Induction of natural killer cell responses by ectromelia virus controls infection. J. Virol. 81: 4070-4079.
44. Rodriguez F, Slifka MK, Harkins S, Whitton JL. 2001. Two overlapping subdominant epitopes identified by DNA immunization induce protective CD8(+) T-cell populations with differing cytolytic activities. J. Virol. 75: 7399-7409.
45. b-binding peptides from influenza virus: effect of non-anchor residues on stability and immunodominance. Mol. Immunol. 32: 623-632.
46. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA. 2004. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78: 7052-7060.
47. Toebes M, Rodenko B, Ovaa H, Schumacher TN. 2009. Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr. Protoc. Immunol. Chapter 18:Unit 18.16.
48. Tscharke DC, et al. 2005. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201: 95-104.
49. van der Most RG, et al. 1997. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J. Virol. 71: 5110-5114.
50. b-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology. 240: 158-167.
51. van der Most RG, et al. 1996. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157: 5543-5554.
52. Virgin HW. 2007. Pathogenesis of viral infection, p 335-336. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
53. von Herrath MG, Dockter J, Nerenberg M, Gairin JE, Oldstone MB. 1994. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. 180: 1901-1910.
54. Wallace GD, Buller RM, Morse HC III. 1985. Genetic determinants of resistance to ectromelia (mousepox) virus-induced mortality. J. Virol. 55: 890-891.
55. West EE, et al. 2011. Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity. 35: 285-298.
56. Whitton JL, Sheng N, Oldstone MB, McKee TA. 1993. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 67: 348-352.
57. Wolint P, Betts MR, Koup RA, Oxenius A. 2004. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J. Exp. Med. 199: 925-936.
58. Xu RH, Fang M, Klein-Szanto A, Sigal LJ. 2007. Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. Proc. Natl. Acad. Sci. U. S. A. 104: 10992-10997.
59. Yewdell JW. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity. 25: 533-543.
60. Yewdell JW, Bennink JR. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88.
61. Yuen TJ, et al. 2010. Analysis of A47, an immunoprevalent protein of vaccinia virus, leads to a reevaluation of the total antiviral CD8+ T cell response. J. Virol. 84: 10220-10229.